摘要
葡萄膜黑色素瘤是成人最常见的眼内原发恶性肿瘤,虽然相对罕见,但极度恶性,且治疗效果不佳。尽管目前针对其原发病灶的治疗可以达理想的局部控制,但仍然有近一半的患者发生远处转移。此文结合当前诊疗技术的新进展,就葡萄膜黑色素瘤的流行病学、基因状态、诊断、原发疾病及转移病灶的治疗和预后作一综述。
Uveal melanoma is the most common primary intraocular malignancy in adults. Although it is relatively rare, it is extremely malignant, with poor treatment effect. The current treatment for primary lesions can achieve ideal local control, but there are still nearly half of the patients with distant metastasis. This article reviews the epidemiology, genetic status, diagnosis, treatment and prognosis of uveal melanoma in combination with recent advances in diagnostic and therapeutic techniques.
引文
1Mclaughlin CC,Wu XC,Jemal A,et al.Incidence of noncutaneousmelanomas in the U.S..Cancer,2005,103(5):1000-1007.
2Singh AD,Topham A.Incidence of uveal melanoma in the UnitedStates:1973-1997.Ophthalmology,2003,110(5):956-961.
3Chang AE,Karnell LH,Menck HR.The National Cancer Data Basereport on cutaneous and noncutaneous melanoma:a summary of84,836 cases from the past decade.The American College ofSurgeons Commission on Cancer and the American CancerSociety.Cancer,1998,83(8):1664-1678.
4Shields CL,Furuta M,Thangappan A,et al.Metastasis of uvealmelanoma millimeter-by-millimeter in 8033 consecutive eyes.Arch Ophthalmol,2009,127(8):989-998.
5Liu YM,Li Y,Wei WB,et al.Clinical characteristics of 582 patientswith uveal melanoma in China.PLoS One,2015,10(12):e0144562.
6Cerbone L,Van Ginderdeuren R,Van den Oord JA,et al.Clinicalpresentation,pathological features and natural course of metastaticuveal melanoma,an orphan and commonly fatal disease.Oncology,2014,86(3):185-189.
7Virgili G,Gatta G,Ciccolallo L,et al.Survival in patients with uvealmelanoma in Europe.Arch Ophthalmol,2008,126(10):1413-1418.
8Kujala E,M?kitie T,Kivel?T.Very long-term prognosis of patientswith malignant uveal melanoma.Invest Ophthalmol Vis Sci,2003,44(11):4651-4659.
9Rietschel P,Panageas KS,Hanlon C,et al.Variates of survival inmetastatic uveal melanoma.J Clin Oncol,2005,23(31):8076-8080.
10Singh AD,Turell ME,Topham AK.Uveal melanoma:trends inincidence,treatment,and survival.Ophthalmology,2011,118(9):1881-1885.
11Virgili G,Gatta G,Ciccolallo L,et al.Incidence of uveal melanomain Europe.Ophthalmology,2007,114(12):2309-2315.
12Hu DN,Yu GP,Mccormick SA,et al.Population-based incidenceof uveal melanoma in various races and ethnic groups.AmJ Ophthalmol,2005,140(4):612-617.
13Andreoli MT,Mieler WF,Leiderman YI.Epidemiological trends inuveal melanoma.Br J Ophthalmol,2015,99(11):1550-1553.
14Shields CL,Kaliki S,Arepalli S,et al.Uveal melanoma in childrenand teenagers.Saudi J Ophthalmol,2013,27(3):197-201.
15Singh AD,Schoenfield LA,Bastian BC,et al.Congenital uvealmelanoma?.Surv Ophthalmol,2016,61(1):59-64.
16Shields CL,Kaliki S,Cohen MN,et al.Prognosis of uvealmelanoma based on race in 8100 patients:the 2015 Doyne Lecture.Eye(Lond),2015,29(8):1027-1035.
17Vajdic CM,Kricker A,Giblin M,et al.Eye color and cutaneousnevi predict risk of ocular melanoma in Australia.Int J Cancer,2001,92(6):906-912.
18Weis E,Shah CP,Lajous M,et al.The association between hostsusceptibility factors and uveal melanoma:a meta-analysis.ArchOphthalmol,2006,124(1):54-60.
19Onken MD,Worley LA,Ehlers JP,et al.Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.Cancer Res,2004,64(20):7205-7209.
20Field MG,Harbour JW.Recent developments in prognostic and predictive testing in uveal melanoma.Curr Opin Ophthalmol,2014,25(3):234-239.
21Harbour JW,Onken MD,Roberson ED,et al.Frequent mutation of BAP1 in metastasizing uveal melanomas.Science,2010,330(69):1410-1413.
22Harbour JW,Roberson ED,Anbunathan HA,et al.Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.Nat Genet,2013,45(2):133-135.
23Onken MD,Worley LA,Long MD,et al.Oncogenic mutations in GNAQ occur early in uveal melanoma.Invest Ophthalmol Vis Sci,2008,49(12):5230-5234.
24van Raamsdonk CD,Bezrookove V,Green GA,et al.Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.Nature,2009,457(7229):599-602.
25Van Raamsdonk CD,Griewank KG,Crosby MB,et al.Mutations in GNA11 in uveal melanoma.N Engl J Med,2010,363(23):2191-2199.
26Martin M,Ma?h?fer L,Temming P,et al.Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.Nat Genet,2013,45(8):933-936.
27Jensen DE,Proctor M,Marquis ST,et al.BAP1:a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.Oncogene,1998,16(9):1097-1112.
28Johansson P,Aoude LG,Wadt K,et al.Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.Oncotarget,2016,7(4):4624-4631.
29Dono M,Angelini G,Cecconi M,et al.Mutation frequencies of GNAQ,GNA11,BAP1,SF3B1,EIF1AX and TERT in uveal melanoma:detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.Br J Cancer,2014,110(4):1058-1065.
30Koopmans AE,Verdijk RM,Brouwer RW,et al.Clinical significance of immunohistochemistry for detection of BAP1mutations in uveal melanoma.Mod Pathol,2014,27(10):1321-1330.
31van de Nes JA,Nelles J,Kreis S,et al.Comparing the prognostic value of BAP1 mutation pattern,chromosome 3 status,and BAP1immunohistochemistry in uveal melanoma.Am J Surg Pathol,2016,40(6):796-805.
32Decatur CL,Ong E,Garg N,et al.Driver mutations in uveal melanoma associations with gene expression profile and patient outcomes.JAMA Ophthalmol,2016,134(7):728-733.
33Ewens KG,Kanetsky PA,Richards-Yutz JA,et al.Chromosome3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.Invest Ophthalmol Vis Sci,2014,55(8):5160-5167.
34Xu C,Wu QX,Tan LJ,et al.Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.Oncogene,2014,33(39):4724-4734.
35Daniels AB,Lee JE,Macconaill LE,et al.High throughput mass spectrometrybased mutation profiling of primary uveal melanoma.Invest Ophthalmol Vis Sci,2012,53(11):6991-6996.
36Bauer J,Kilic E,Vaarwater J,et al.Oncogenic GNAQ mutations arenot correlated with disease-free survival in uveal melanoma.BrJ Cancer,2009,101(5):813-815.
37Koopmans AE,Vaarwater J,Paridaens D,et al.Patient survival inuveal melanoma is not affected by oncogenic mutations in GNAQnd GNA11.Br J Cancer,2013,109(2):493-496.
38Weber A,Hengge UR,Urbanik D,et al.Absence of mutations ofthe BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.Lab Invest,2003,83(12):1771-1776.
39Zuidervaart W,van Nieuwpoort F,Stark M,et al.Activation of theMAPK pathway is a common event in uveal melanomas although itrarely occurs through mutation of BRAF or RAS.Br J Cancer,2005,92(11):2032-2038.
40von Euw E,Atefi M,Attar N,et al.Antitumor effects of theinvestigational selective MeK inhibitor TAK733 against cutaneousand uveal melanoma cell lines.Mol Cancer,2012,11:22.
41Mahipal A,Tijani L,Chan K,et al.A pilot study of sunitinib malatein patients with metastatic uveal melanoma.Melanoma Res,2012,22(6):440-446.
42Carvajal RD,Sosman JA,Quevedo JF,et al.Effect of selumetinib vschemotherapy on progression-free survival in uveal melanomaa randomized clinical trial.JAMA,2014,311(23):2397-2405.
43Golas MM,Sander B,Will CL,et al.Molecular architecture of themultiprotein splicing factor SF3b.Science,2003,300(5621):980-984.
44te Raa GD,Derks I,Navrkalova V,et al.The impact of SF3B1mutations in CLL on the DNA-damage response.Leukemia,2015,29(5):1133-1142.
45Furney SJ,Pedersen M,Gentien D,et al.SF3B1 mutations areassociated with alternative splicing in uveal melanoma.CancerDiscov,2013,3(10):1122-1129.
46Yavuzyigitoglu S,Koopmans AE,Verdijk RM,et al.Uvealmelanomas with SF3B1 mutations a distinct subclass associatedwith late-onset metastases.Ophthalmology,2016,123(5):1118-1128.
47Eskelin S,Kivela T.Mode of presentation and time to treatment ofuveal melanoma in Finland.Br J Ophthalmol,2002,86(3):333-338.
48The Collaborative Ocular Melanoma Study Group.Factorspredictive of growth and treatment of small choroidal melanoma:COMS Report.Arch Ophthalmol,1997,115(12):1537-1544.
49Collaborative Ocular Melanoma Study Group.Accuracy ofdiagnosis of choroidal melanomas in the Collaborative OcularMelanoma Study.COMS report no.1.Arch Ophthalmol,1990,108(9):1268-1273.
50Shields CL,Shields JA,Perez N,et al.Primary transpupillarythermotherapy for small choroidal melanoma in 256 consecutivecases:outcomes and limitations.Ophthalmology,2002,109(2):225-234.
51Yarovoy AA,Magaramov DA,Bulgakova ES.The comparison ofruthenium brachytherapy and simultaneous transpupillarythermotherapy of choroidal melanoma with brachytherapy alone.Brachytherapy,2012,11(3):224-229.
52Tarmann L,Wackernagel W,Avian A,et al.Ruthenium-106plaque brachytherapy for uveal melanoma.Br J Ophthalmol,2015,99(12):1644-1649.
53Collaborative Ocular Melanoma Study Group.The COMSrandomized trial of iodine 125 brachytherapy for choroidalmelanoma:V.Twelve-year mortality rates and prognostic factors:COMS report No.28.Arch Ophthalmol,2006,124(12):1684-1693.
54Sagoo MS,Shields CL,Mashayekhi AA,et al.Plaque radiotherapyfor juxtapapillary choroidal melanoma tumor control in 650consecutive cases.Ophthalmology,2011,118(2):402-407.
55Gragoudas E,Li WJ,Goitein M,et al.Evidence-based estimates ofoutcome in patients irradiated for intraocular melanoma.ArchOphthalmol,2002,120(12):1665-1671.
56Mishra KK,Quivey JM,Daftari IK,et al.Long-term results of theUCSF-LBNL randomized trial:charged particle with helium ionversus iodine-125 plaque therapy for choroidal and ciliary bodymelanoma.Int J Radiat Oncol Biol Phys,2015,92(2):376-383.
57Walker TM,Van Ginkel PR,Gee RL,et al.Expression ofangiogenic factors Cyr61 and tissue factor in uveal melanoma.Arch Ophthalmol,2002,120(12):1719-1725.
58Desjardins L,Dorval T,Lévy C,et al.Randomised study onadjuvant therapy by DTIC in choroidal melanoma.Ophtalmogie,1998,12(3):168-173.
59Lane AM,Egan KM,Harmon D,et al.Adjuvant interferon therapyfor patients with uveal melanoma at high risk of metastasis.Ophthalmology,2009,116(11):2206-2212.
60Voelter V,Schalenbourg A,Pampallona S,et al.Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.Melanoma Res,2008,18(3):220-224.
61Surriga O,Rajasekhar VK,Ambrosini GA,et al.Crizotinib,a c-Metinhibitor,prevents metastasis in a metastatic uveal melanomamodel.Mol Cancer Ther,2013,12(12):2817-2826.
62Valsecchi ME,Orloff M,Sato R,et al.Adjuvant sunitinib in high-risk patients with uveal melanoma comparison with institutionalcontrols.Ophthalmology,2018,125(2):210-217.
63Landreville S,Agapova OA,Matatall KA,et al.Histone deacetylaseinhibitors induce growth arrest and differentiation in uvealmelanoma.Clin Cancer Res,2012,18(2):408-416.
64Collaborative Ocular Melanoma Study Group.Assessment ofmetastatic disease status at death in 435 patients with largechoroidal melanoma in the Collaborative Ocular Melanoma Study(COMS):COMS report no.15.Arch Ophthalmol,2001,119(15):670-676.
65Mariani P,Piperno-Neumann S,Servois V,et al.Surgicalmanagement of liver metastases from uveal melanoma:1.6 years’experience at the Institut Curie.Eur J Surg Oncol,2009,35(11):1192-1197.
66Frenkel S,Nir I,Hendler K,et al.Long-term survival of uvealmelanoma patients after surgery for liver metastases.BrJ Ophthalmol,2009,93(8):1042-1046.
67Leyvraz S,Piperno-Neumann S,Suciu S,et al.Hepatic intra-arterial versus intravenous fotemustine in patients with livermetastases from uveal melanoma:a multicentric randomized trial.Ann Oncol,2014,25(EORTC 18021):742-746.
68Pingpank JF,Hughes MS,Faries HR,et al.A phaseⅢrandomassignment trial comparing percutaneous hepatic perfusion withmelphalan(PHP-mel)to standard of care for patients with hepaticmetastases from metastatic ocular or cutaneous melanoma.J ClinOncol,2010,28(18_Suppl):LBA8512-LBA8512.
69Bedikian AY,Legha SS,Mavligit G,et al.Treatment of uvealmelanoma metastatic to the liver:a review of the M.D.Anderson Cancer Center experience and prognostic factors.Cancer,1995,76(9):1665-1670.
70Zimmer L,Vaubel J,Mohr P,et al.PhaseⅡDeCOG-study ofipilimumab in pretreated and treatment-naive patients withmetastatic uveal melanoma.PLoS One,2015,10(3):e0118564.
71Joshua AM,Monzon JG,Mihalcioiu C,et al.A phase 2 study oftremelimumab in patients with advanced uveal melanoma.Melanoma Res,2015,25(4):342-347.
72Piperno-Neumann S,Servois V,Mariani P.Activity of anti-PD1drugs in uveal melanoma patients.J Clin Oncol,2016,34(15_Suppl):9588.
73Sato T,Nathan PD,Hernandez-Aya LF,et al.Intra-patientescalation dosing strategy with IMCgp100 results in mitigation ofT-cell based toxicity and preliminary efficacy in advanced uvealmelanoma.J Clin Oncol,2017,35(15_Suppl):9531.
74Shoushtari AN,Kudchadkar RR,Panageas K,et al.A randomizedphase 2 study of trametinib with or without GSK2141795 inpatients with advanced uveal melanoma.J Clin Oncol,2016,34(15_Suppl):9511.
75Piperno-Neumann S,Kapiteijn E,Larkin JM,et al.PhaseⅠdose-escalation study of the protein kinase C(PKC)inhibitor AEB071 inpatients with metastatic uveal melanoma.J Clin Oncol,2014,32(15_Suppl):9030.
76Komatsubara KM,Shoushtari AN,Feun L.A phaseⅠb study ofAEB071,a PKC inhibitor,and BYL719,a PI3Ka inhibitor,in patients with metastatic uveal melanoma(UM)//14th International Congress of the Society for Melanoma Research.Brisbane,Australia:Society for Melanoma Research,2017.
77Shields CL,Kaliki S,Furuta M,et al.American joint committee oncancer classification of posterior uveal melanoma(tumor sizecategory)predicts prognosis in 7731 patients.Ophthalmology,2013,120(10):2066-2071.
78Khoja L,Atenafu EG,Joshua AM.Meta-analysis of phaseⅡtrialsin metastatic uveal melanoma(MUM)to determine progression-free(PFS)and overall survival(OS)benchmarks for future phaseⅡtrials:an irci-ocular melanoma initiative.J Clin Oncol,2016,34(15_Suppl):9567.
79Versluis M,de Lange MJ,van Pelt SI,et al.Digital PCR validates 8qdosage as prognostic tool in uveal melanoma.PLoS One,2015,10:e0116371.
80Field MG,Decatur CL,Kurtenbach SA,et al.PRAME as anIndependent biomarker for metastasis in uveal melanoma.ClinCancer Res,2016,22(5):1234-1242.
81Robertson AG,Shih J,Yau C,et al.Integrative analysis identifiesfour molecular and clinical subsets in uveal melanoma.CancerCell,2017,32(2):204-220.
